Niihara Yutaka's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Jan 3, 2022
- Accession no.
- 0001209191-22-000164
- Filed
- Jan 3, 2022
- Trade date
- Dec 28-31, 2021
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $27.5K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niihara YutakaCIK 0001517691 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +1,000 | $1.60 | +$1,600 | 11,125,656 | Direct | |
| Dec 29, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +2,700 | $1.57 | +$4,239 | 11,128,356 | Direct | |
| Dec 30, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +6,800 | $1.56 | +$10,608 | 11,135,156 | Direct | |
| Dec 31, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +7,000 | $1.58 | +$11,060 | 11,142,156 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.